Sunitinib Malate

Description: Sunitinib Malate (Sunitinib) is an indolinone-based tyrosine kinase inhibitor. It blocks the tyrosine kinase activities of VEGFR2, PDGFRbeta (IC50: 80/2 nM), and c-kit. Target: VEGFR, c-Kit, Autophagy, FLT, PDGFR, IRE1, Apoptosis, Mitophagy. Smiles: O[C@@H](CC(O)=O)C(O)=O.CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C. References: Sun L, et al. Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase. J Med Chem. 2003 Mar 27,46(7):1116-9.